A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

672 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-01

Study Completion Date

2022-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this trial, the investigators are assessing whether giving an increased dose of rifampicin to patients receiving the standard treatment for tuberculosis is safe and, when given for 4 months only, will also result in greater and faster killing of the tubercle bacillus in the lungs and result in relapse rates similar to those found in the World Health Organisation (WHO) recommended standard 6 month regimen.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

NCT02410772

Tuberculosis

COMPLETED PHASE3

Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB

NCT01392911

Pulmonary Tuberculosis (TB)

COMPLETED PHASE2

Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy

NCT03982277

Tuberculosis

COMPLETED PHASE2

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

NCT00023452

Tuberculosis

COMPLETED PHASE3

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

NCT03474029

Latent Tuberculosis

RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type of design An open-label 3-arm trial to compare a standard 6-month control regimen with two 4-month treatment regimens for the treatment of tuberculosis (TB).

Disease/patients studied The trial will include 654 patients newly diagnosed with pulmonary TB with sputum positive or negative for TB on microscopy but with a positive result on a GeneXpert Test with organisms fully sensitive to rifampicin

The treatment regimens - Control and Experimental

Patients enrolled in the trial will be randomly allocated to receive one of the following three chemotherapy treatment regimens:

1. Control regimen (R10): The standard regimen of isoniazid, pyrazinamide and ethambutol plus 10 mg/kg rifampicin for the initial 8 weeks, followed by isoniazid and rifampicin (at the same dose size) for an additional 4 months (2HRZE/4HR)A.
2. Study regimen 1(SR1): 2 months of daily ethambutol, isoniazid, rifampicin, and pyrazinamide followed by 2 months of daily isoniazid and rifampicin. A supplement of either 450 mg (weight bands 35-39kg and 40-54kg) or 600mg (weight band 55-69kg and 70 and more kg) of rifampicin will be given throughout the four months (2EHR 1200Z/2HR1200)B.
3. Study regimen 2(SR2): 2 months of daily ethambutol, isoniazid, rifampicin, and pyrazinamide followed by 2 months of daily isoniazid and rifampicin. A supplement of either 450 mg (weight bands 35-39kg and 40-54kg) or 600mg (weight band 55-69kg and 70 and more kg) of rifampicin will be given throughout the four months (2EHR1800Z/2HR1800)C.

1.1 Outcome measures Primary outcome measure

1. Since the objective of the trial is to reduce treatment duration by increasing the dose of rifampicin, the primary outcome measure is the combined rate of failure at the end of treatment and relapse during the subsequent 12 months in smear positive patients.
2. The occurrence of grade 3 or 4 adverse events at any time during chemotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rifampicin 150mg (Control)

2 months daily 4FDC - Rifampicin 150mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 4 months daily 2FDC - Rifampicin 150mg and Isoniazid 75mg (continuous phase)

Group Type ACTIVE_COMPARATOR

Ethambutol

Intervention Type DRUG

Ethambutol 275mg - all arms

Pyrazinamide

Intervention Type DRUG

Pyrazinamide 400mg - all arms

Rifampicin

Intervention Type DRUG

Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)

Isoniazid

Intervention Type DRUG

Isoniazid 75mg - all arms

Rifampicin 1200mg (Regimen 1)

2 months daily 4FDC - high dose Rifampicin 1200mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1200mg and Isoniazid 75mg (continuous phase)

Group Type EXPERIMENTAL

Ethambutol

Intervention Type DRUG

Ethambutol 275mg - all arms

Pyrazinamide

Intervention Type DRUG

Pyrazinamide 400mg - all arms

Rifampicin

Intervention Type DRUG

Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)

Isoniazid

Intervention Type DRUG

Isoniazid 75mg - all arms

Rifampicin 1800mg (Regimen 2)

2 months daily 4FDC - high dose Rifampicin 1800mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1800mg and Isoniazid 75mg (continuous phase)

Group Type EXPERIMENTAL

Ethambutol

Intervention Type DRUG

Ethambutol 275mg - all arms

Pyrazinamide

Intervention Type DRUG

Pyrazinamide 400mg - all arms

Rifampicin

Intervention Type DRUG

Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)

Isoniazid

Intervention Type DRUG

Isoniazid 75mg - all arms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ethambutol

Ethambutol 275mg - all arms

Intervention Type DRUG

Pyrazinamide

Pyrazinamide 400mg - all arms

Intervention Type DRUG

Rifampicin

Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)

Intervention Type DRUG

Isoniazid

Isoniazid 75mg - all arms

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. GeneXpert sputum positive, rifampicin susceptible, newly diagnosed pulmonary tuberculosis will be included even if they are microscopy negative.
2. No previous anti-tuberculosis chemotherapy.
3. Patients ≥ 18 years
4. Consent to participation in the trial and to HIV testing
5. Provide informed consent.
6. Patient has a stable home address within easy reach of the treatment facility and likely to remain there for the next 18 months.
7. Pre-menopausal women must be using a barrier form of contraception or be surgically sterilised or have an Intrauterine Contraceptive Device (IUCD) in place for the duration of the treatment phase

Exclusion Criteria

1. Patients with rifampicin resistance identified by GeneXpert or by direct susceptibility testing (late exclusions).
2. Has any condition that may prove fatal during the study period.
3. Has TB meningitis.
4. Has pre-existing non-tuberculous disease likely to prejudice the response to, or assessment of, treatment e.g. insulin-dependent diabetes, liver or kidney disease, blood disorders, peripheral neuritis, and severe thrombocytopenia, rash, increase of bilirubin and other diseases that are likely to be contraindicated with rifampicin
5. Is female and known to be pregnant, or breast feeding.
6. Is suffering from a condition likely to lead to uncooperative behaviour such as psychiatric illness or alcoholism.
7. Has contraindications to any medications in the study regimens
8. Is HIV positive
9. Haemoglobin \<7g/l
10. Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) \> 5 times the upper limit of normal (ULN) for that laboratory
11. Creatinine clearance (CrCl) of \< 30mls/min. Calculated as CrCl (mL/min) = N x \[140-age (years)\] x weight (kg) Serum creatinine (micromol/L) Where N = 1.23 males, 1.04 females
12. Has glucose in urine
13. Weight \< 35kg

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No